Actualités et communiqués de presse Celcuity 2026 | CELC | ISIN US15102K1007

Actualités Eulerpool Celcuity

04/05/2026 14:05:21

US-Börsen unter dem Einfluss des Iran-Konflikts und Unternehmensnachrichten

Actualités de l'action Celcuity

Celcuity est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Celcuity.

30 octobre·
SeekingAlpha
Celcuity: Stronger Clinical Evidence, Much Lower Valuation
22 octobre·
Benzinga
Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140
8 octobre·
Yahoo
Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event
30 septembre·
Yahoo
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
30 septembre·
Benzinga
Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive
28 septembre·
Yahoo
Is Celcuity (CELC) Stock a Buy?
18 septembre·
SeekingAlpha
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion
17 septembre·
Benzinga
JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
11 septembre·
Benzinga
10 Health Care Stocks With Whale Alerts In Today’s Session
9 septembre·
SeekingAlpha
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
10 mars·
SeekingAlpha
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
10 mars·
Benzinga
Needham Maintains Buy on Celcuity, Raises Price Target to $122
9 mars·
Benzinga
Celcuity Reveals Publication Of Efficacy And Safety Results From The PIK3CA Wild-Type Cohort Of The Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, An Investigational Pan-PI3K/mTORC1/2 Inhibitor, In The Journal Of Clinical Oncology
9 mars·
SeekingAlpha
Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
2 mars·
SeekingAlpha
Artisan International Small-Mid Fund Q4 2025 Performance Review
16 février·
Yahoo
What Celcuity (CELC)'s Board Addition of Veteran Oncology Executive Means For Shareholders
13 février·
SeekingAlpha
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
13 février·
Yahoo
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?
13 février·
Yahoo
Soleus Adds a Significant Number of Celcuity Shares
12 février·
Yahoo
Celcuity Appoints Charles Romp to its Board of Directors

Communiqués de presse relatifs à l'action Celcuity

Celcuity publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

22 novembre•
Celcuity
Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
10 novembre•
Celcuity
Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
10 novembre•
Celcuity
Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
3 novembre•
Celcuity
Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
14 septembre•
Celcuity
Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
11 août•
Celcuity
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4 août•
Celcuity
Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call
3 août•
Celcuity
Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference
18 juillet•
Celcuity
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
26 mai•
Celcuity
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
16 mai•
Celcuity
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
16 mai•
Celcuity
Celcuity Inc. Announces $100 Million Private Placement
9 mai•
Celcuity
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
5 avril•
Celcuity
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
23 mars•
Celcuity
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
16 mars•
Celcuity
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
2 mars•
Celcuity
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
18 janvier•
Celcuity
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
10 décembre•
Celcuity
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
2 décembre•
Celcuity
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
29 novembre•
Celcuity
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
15 novembre•
Celcuity
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
9 novembre•
Celcuity
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
8 novembre•
Celcuity
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
29 octobre•
Celcuity
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
9 août•
Celcuity
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
5 août•
Celcuity
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
2 août•
Celcuity
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
8 juillet•
Celcuity
Celcuity to Participate in the William Blair Biotech Focus Conference
28 juin•
Celcuity
Celcuity Announces Pricing of Follow-on Offering

Celcuity News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Celcuity (CELC, ISIN : US15102K1007). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Celcuity.

Celcuity Action

Celcuity Celcuity Inc est une société biotechnologique fondée par Brian Sullivan en 2012. Le siège social de l'entreprise est situé à Minneapolis, aux États-Unis.